Silverback Therapeutics/SPRY

$9.02

-2.38%
-
1D1W1MYTD1YMAX

About Silverback Therapeutics

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Ticker

SPRY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Lowenthal

Employees

24

Headquarters

San diego, United States

SPRY Metrics

BasicAdvanced
$870.44M
Market cap
-
P/E ratio
-$0.57
EPS
0.84
Beta
-
Dividend rate
$870.44M
0.84276
$11.27
$2.55
663.02K
96.916
-21.13%
-21.59%
-21.45%
29,014.8
3.769
3.772
-97.72%
54.42%

What the Analysts think about SPRY

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 2 analysts.
110.64% upside
High $19.00
Low $19.00
$9.02
Current price
$19.00
Average price target

SPRY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-7.1M
-52.03%
Profit margin
0%
-

SPRY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 50%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.16
-$0.18
-$0.16
-$0.07
-
Expected
-$0.17
-$0.17
-$0.18
-$0.14
-$0.11
Surprise
-4.57%
3.65%
-12.41%
-50%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Silverback Therapeutics stock?

Silverback Therapeutics (SPRY) has a market cap of $870.44M as of April 14, 2024.

What is the P/E ratio for Silverback Therapeutics stock?

The price to earnings (P/E) ratio for Silverback Therapeutics (SPRY) stock is 0 as of April 14, 2024.

Does Silverback Therapeutics stock pay dividends?

No, Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Silverback Therapeutics dividend payment date?

Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders.

What is the beta indicator for Silverback Therapeutics?

Silverback Therapeutics (SPRY) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Silverback Therapeutics stock price target?

The target price for Silverback Therapeutics (SPRY) stock is $19, which is 110.64% above the current price of $9.02. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Silverback Therapeutics stock

Buy or sell Silverback Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing